Valuation: Astellas Pharma Inc.

Market Cap 4,030B 25.4B 22.77B 21.19B 19.24B 36.26B 2,432B 36.53B 253B 99.66B 1,254B 95.42B 93.32B P/E 2027 *
10.4x
P/E 2028 * 11x
Enterprise Value 3,971B 25.02B 22.44B 20.88B 18.96B 35.72B 2,396B 35.99B 249B 98.19B 1,235B 94.02B 91.95B EV / Sales 2027 *
1.68x
EV / Sales 2028 * 1.61x
Free-Float
98.92%
Yield 2027 *
3.57%
Yield 2028 * 3.7%
1 day-0.02%
1 week+0.11%
Current month-3.15%
1 month+0.31%
3 months+4.93%
6 months-13.79%
Current year+7.38%
1 week 2,216
Extreme 2216
2,288
1 month 2,216
Extreme 2216
2,413
Current year 2,041
Extreme 2041
2,717
1 year 1,557.5
Extreme 1557.5
2,717
3 years 1,243.5
Extreme 1243.5
2,717
5 years 1,243.5
Extreme 1243.5
2,717
10 years 1,243.5
Extreme 1243.5
2,717
Manager TitleAgeSince
Chief Executive Officer 64 2023-02-09
Director of Finance/CFO 55 2023-10-31
Compliance Officer - 2025-03-31
Director TitleAgeSince
Chairman 66 2023-02-09
Director/Board Member 64 2019-05-31
Director/Board Member 59 2023-05-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.02%+0.11%+38.65%+10.20% 25.45B
+0.28%+3.46%+41.89%+93.71% 1,051B
+0.88%+4.27%+38.28%+68.70% 630B
+1.68%+5.78%+21.96%+89.56% 489B
-0.10%+4.24%+69.15%+40.41% 359B
+0.61%+4.14%+24.05%+41.70% 344B
+0.72%+3.11%+14.29%+33.76% 272B
+0.23%+1.31%-5.91%+9.89% 246B
+0.65%+3.62%+42.81%+46.50% 224B
-0.49%+4.01%+27.26%+95.97% 187B
Average +0.44%+2.62%+31.24%+53.04% 382.92B
Weighted average by Cap. +0.56%+2.86%+33.98%+66.52%

Financials

2027 *2028 *
Net sales 2,364B 14.9B 13.36B 12.43B 11.29B 21.27B 1,427B 21.42B 148B 58.45B 735B 55.97B 54.73B 2,206B 13.9B 12.47B 11.6B 10.53B 19.85B 1,331B 20B 139B 54.55B 686B 52.24B 51.08B
Net income 373B 2.35B 2.11B 1.96B 1.78B 3.35B 225B 3.38B 23.39B 9.21B 116B 8.82B 8.63B 349B 2.2B 1.97B 1.84B 1.67B 3.14B 211B 3.16B 21.92B 8.63B 109B 8.27B 8.08B
Net Debt -59.18B -373M -334M -311M -283M -532M -35.72B -536M -3.72B -1.46B -18.41B -1.4B -1.37B -481B -3.03B -2.72B -2.53B -2.3B -4.32B -290B -4.36B -30.18B -11.89B -150B -11.38B -11.13B
Projected Income Statement - Annual - Astellas Pharma Inc.
Logo Astellas Pharma Inc.
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.
Employees
14,099
Date Price Change Volume
26-10-09 ¥2,247.50 -0.02% 5,898,400
26-10-08 ¥2,248.00 -0.33% 5,458,800
26-10-07 ¥2,255.50 +0.53% 5,853,100
26-10-06 ¥2,243.50 +0.38% 5,031,100
Trader
Investor
Global
Quality
ESG MSCI
AA
Ratings Surperformance© - Astellas Pharma Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
2,247.50JPY
Average target price
2,529.29JPY
Spread / Average Target
+12.54%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Astellas Pharma Inc.
  1. Stock Market
  2. Stocks
  3. 4503 Stock